Trial Outcomes & Findings for Dietary Oxalate and Innate Immunity in Kidney Stone Disease (NCT NCT04051346)

NCT ID: NCT04051346

Last Updated: 2026-06-26

Results Overview

Twenty-four hour urinary oxalate will be reported as mg/day.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

14 participants

Primary outcome timeframe

Days 4 and 14

Results posted on

2026-06-26

Participant Flow

Participant milestones

Participant milestones
Measure
Low Oxalate Diet
Subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the high oxalate diet for the final four days, with blood and 24-hour urine collections once again post diet. Low Oxalate Diet: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
High Oxalate Diet
Subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the low oxalate diet for the final four days, with blood and 24-hour urine collections once again post diet. High Oxalate Diet: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
Phase I - 4 days
STARTED
7
7
Phase I - 4 days
COMPLETED
7
7
Phase I - 4 days
NOT COMPLETED
0
0
Washout - 10 Day
STARTED
7
7
Washout - 10 Day
COMPLETED
7
7
Washout - 10 Day
NOT COMPLETED
0
0
Phase II - 4 days
STARTED
7
7
Phase II - 4 days
COMPLETED
7
7
Phase II - 4 days
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Dietary Oxalate and Innate Immunity in Kidney Stone Disease

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Study Participants
n=14 Participants
All Participants were included in the Crossover of both Low Oxalate Diet and High Oxalate Diet.
Age, Categorical
<=18 years
0 Participants
n=20 Participants
Age, Categorical
Between 18 and 65 years
14 Participants
n=20 Participants
Age, Categorical
>=65 years
0 Participants
n=20 Participants
Age, Continuous
41.3 years
STANDARD_DEVIATION 13.6 • n=20 Participants
Sex: Female, Male
Female
9 Participants
n=20 Participants
Sex: Female, Male
Male
5 Participants
n=20 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=20 Participants
Race (NIH/OMB)
Asian
1 Participants
n=20 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=20 Participants
Race (NIH/OMB)
Black or African American
7 Participants
n=20 Participants
Race (NIH/OMB)
White
6 Participants
n=20 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=20 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=20 Participants
Region of Enrollment
United States
14 participants
n=20 Participants

PRIMARY outcome

Timeframe: Days 4 and 14

Twenty-four hour urinary oxalate will be reported as mg/day.

Outcome measures

Outcome measures
Measure
Low Oxalate Diet
n=14 Participants
Subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the high oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet. Low Oxalate Diet: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
High Oxalate Diet
n=14 Participants
Subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the low oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet. High Oxalate Diet: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
Urinary Oxalate Excretion
8.59 mg/day
Standard Error 1
13.97 mg/day
Standard Error 2.38

PRIMARY outcome

Timeframe: Day 4 and 14

Crystalluria will be reported as particles/ml.

Outcome measures

Outcome measures
Measure
Low Oxalate Diet
n=14 Participants
Subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the high oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet. Low Oxalate Diet: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
High Oxalate Diet
n=14 Participants
Subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the low oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet. High Oxalate Diet: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
Crystalluria
816,000,000 particles/ml
Standard Error 90,000,000
850,000,000 particles/ml
Standard Error 96,200,000

PRIMARY outcome

Timeframe: Days 4 and 14

Cellular energetic oxygen consumption traces will be examined.

Outcome measures

Outcome measures
Measure
Low Oxalate Diet
n=14 Participants
Subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the high oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet. Low Oxalate Diet: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
High Oxalate Diet
n=14 Participants
Subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the low oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet. High Oxalate Diet: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
Number of Participants With Monocyte Cellular Energetics
14 Participants
14 Participants

SECONDARY outcome

Timeframe: Days 4 and 14

Monocyte cellular transcriptomics will be determined using RNA sequencing (mRNA).

Outcome measures

Outcome measures
Measure
Low Oxalate Diet
n=14 Participants
Subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the high oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet. Low Oxalate Diet: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
High Oxalate Diet
n=14 Participants
Subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the low oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet. High Oxalate Diet: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
Number of Participants With Monocyte Transcriptomics
14 Participants
14 Participants

Adverse Events

All Study Participants

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Tanecia Mitchell

UAB

Phone: 2059962292

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place